Welcome and Introduction
Nicole Ward
PART ONE: LECTURES
Disease models for biomarker research
Nicole Ward
Psoriasis and psoriatic arthritis biomarkers
Vinod Chandran
Machine learning approaches for psoriasis research
Alex Tsoi
PANEL DISCUSSION
Johann Gudjonsson
PART TWO: POSTER PRESENTATIONS
Introduction to Session
Johann Gudjonsson
POSTER PRESENTATIONS
Transethnic analysis of psoriasis susceptibility in South Asians and Europeans enhances fine-mapping in the MHC and genomewide
James T. Elder, MD, PhD – University of Michigan, Ann Arbor, Michigan, United States
Single cell transcriptomic analysis of the peripheral neutrophil compartment in psoriatic arthritis reveals heterogeneity and novel potential therapeutic targets
Cheryl Cameron, PhD – Case Western Reserve University, Cleveland, Ohio, United States
Perspective of psoriatic disease patients on novel COVID-19 vaccines
George Gondo, MA – National Psoriasis Foundation, Portland, Oregon, United States
Comparing the pediatric and adult plaque psoriasis transcriptomes
Wynnis Tom, MD – University of California San Diego, San Diego, California, United States
Closing Comments
Johann Gudjonsson
IPC Jr. Councilor Towhida Noor reviews the psoriasis pipeline: selective TYK2 inhibitors, long-acting IL-17 and IL-23 biologics, and IL-36 blockade in GPP.
IPC Board Member and Treasurer Joel Gelfand, MD, MSCE, is the editor of a new textbook, Psoriasis: An Expert Global Perspective, now available for preorder from Elsevier. He worked with associate editors IPC President Bruce Strober, MD, PhD; IPC Vice President/President-Elect Claudia de la Cruz, MD; and IPC Chief Medical Officer Peter van de Kerkhof, MD, PhD. Nearly 50 authors from 20 countries contributed 30 chapters covering psoriasis from its earliest descriptions through genetics, immunology, and current therapies, with clinical images of psoriasis across diverse skin tones. All royalties support IPC.
PRE-ORDER YOUR COPY
In this video, IPC Councilor Rodrigo Garcia Salinas, MD, a rheumatologist from Argentina, explains how to recognize psoriatic arthritis early, including why joint pain, how long a patient has had psoriasis, and family history can matter more than skin severity alone. He also reviews how imaging helps catch early disease and how to choose treatment based on each patient’s joint, spine, and skin involvement.
IPC President Bruce Strober reviews the link between psoriasis and metabolic disease, drawing on findings from IPC’s recent paper in the Journal of the American Academy of Dermatology (JAAD). He translates this growing body of evidence into five concrete priorities from the 2025 IPC Think Tank for improving cardiometabolic screening and care.
